Open-label for Opioid Use Disorder
This trial is looking at the effects of adding psilocybin to a buprenorphine/naloxone regimen in people with OUD. They will be looking at things like adverse events, quality of life, and pain.
- Opioid Use Disorder
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the current enrollment size of this trial?
"No longer taking on patients, this medical trial was first published in January 2021 and last modified in August 2022. However, if you are still searching for clinical trials related to drug abuse there are currently 533 studies recruiting participants and 33 clinical trials involving psilocybin with guided counseling also admitting people."
What other exploratory investigations have been done utilizing Psilocybin in conjunction with counseling?
"At present, 33 trials investigating the effects of psilocybin with counceling are in progress. None have advanced to a phase 3 trial yet; however, 36 medical centres across multiple locations are testing this approach. Notably, there is an increase in Vancouver-based studies exploring the efficacy of this method."
Are minors being accepted as participants in this experiment?
"The minimum age of admission to this clinical trial is 21 and the maximum allowed age is 65."
Am I able to join this clinical experiment?
"This medical trial is seeking 10 participants who have a history of drug abuse and are between the ages 21 to 65."
Are there any current opportunities to participate in the trial?
"Unfortunately, this research is no longer accepting patients. It was initially listed on January 13th 2021 and had its last update on August 19th 2022. However, there are currently 533 trials related to drug abuse that still have openings as well as 33 studies with Psilocybin supported therapy that need participants."
Is the combination of Psilocybin and directed consultation sanctioned by the FDA?
"The safety rating of Psilocybin with guided counseling is a 1 given that this trial is in Phase 1, hence there are only limited evidence to demonstrate its efficacy and security."